Clive Wilson is the J. P. Todd Professor of Pharmaceutics at Strathclyde University and serves on the European Union Federation of Pharmaceutical Sciences teaching and overseas liaison committee. He completed his Ph.D. with Professor Dennis Parke in drug metabolism at the University of Surrey. His first position was an Asthma Research Council Fellow at the Cardiothoracic Institute, London becoming a Lecturer in Biochemical Pharmacology and moving to Nottingham Medical School to become Reader in Applied Pharmacology.
Major areas of research have been the study of the behaviour of drug formulations in man. With colleagues at Nottingham, he pioneered applications of scintigraphy in the study of physiological and patho-physiological effects on drug absorption following oral, nasal, pulmonary and ophthalmic delivery. In the university, his group collaborates with industry on ophthalmic drug delivery projects especially related to the behaviour of ocular implants. He is a member of the steering group of the IMI OrBiTo programme and co-manages the Strathclyde group with Professor Gavin Halbert. Recent new areas of interest include additive soft and hard matrix technologies for drug delivery, and several programmes in novel therapies for treating ulcerative colitis.
Primary Teaching activities are in the field of Biopharmaceutics and formulation research.
Steering Group, European Federation for Pharmaceutical Sciences
- European Federation of Pharmaceutical Sciences (External organisation)
- EUFEPS Conference on Bioavailability and Bioequivalence , Greece
- Keynote/plenary speaker
- CRS Book Series Editorial Board
- Editorial board member
- 34th Controlled Release Society Conference, USA
- Keynote/plenary speaker
- 10th Rotterdam Glaucoma Symposium, Netherlands
- Keynote/plenary speaker
- Philips Medimetrics (External organisation)
More professional activities
- Retinal Drug Delivery
- Khadra, Ibrahim (Principal Investigator) Wilson, Clive (Principal Investigator) Dunn, Claire (Researcher)
- The Allergan project focuses on API infused PLGA implants for ocular drug delivery. These implants are bio-degradable meaning there is no need for surgical removal of the implant. The research currently focuses on investigating the degradation of the implants at 37oC (body temperature) and 50oC (to develop an accelerated degradation model) and observing if agitation has a significant effect on degradation rate. Implants were then fully characterised to determine the physical and chemical degradation effects.
- 01-Jan-2017 - 31-Jan-2019
- EPSRC Doctoral Training Grant - DTA, University of Strathclyde | Brownlee, William John
- Seib, Philipp (Principal Investigator) Wilson, Clive (Co-investigator) Brownlee, William John (Research Co-investigator)
- 01-Jan-2015 - 11-Jan-2019
- EPSRC Doctoral Training Grant - DTA, University of Strathclyde | Huff Guelbert, Samuel
- Seib, Philipp (Principal Investigator) Wilson, Clive (Co-investigator) Huff Guelbert, Samuel (Research Co-investigator)
- 01-Jan-2013 - 17-Jan-2017
- Medical Devices Doctoral Training Centre Renewal | Hall Barrientos, Ivan
- Wilson, Clive (Principal Investigator) Black, Richard Anthony (Co-investigator) Hall Barrientos, Ivan (Research Co-investigator)
- 01-Jan-2013 - 29-Jan-2018
- Optical and Magnetic Non-Invasive Flow and manipulation platform for controlling nanomanufacture of pharmaceuticals, nanoparticles, and other nanostructured materials
- Haw, Mark (Principal Investigator) Wilson, Clive (Co-investigator) Zagnoni, Michele (Co-investigator) Wark, Alastair (Co-investigator)
- micromanipulation non-invasively in nanomaterial manufacture processes, to enhance direct control of nucleation, growth and structure development. Nucleation and assembly are the first stage of engineering nanostructured materials in applications including drug crystallisation, nanoparticle and nanoporous catalyst manufacture, and metal-organic frameworks for molecular storage. There is significant evidence that these complex microscale nucleation and assembly processes are strongly affected by local conditions such as flow. Our understanding of how flow and local (at the micron-scale) forces affect and thus could be used to control nanostructure nucleation is limited, because nucleation is inherently a local process while flow and external forces are usually applied globally. Therefore our novel, versatile OMNIFlow experimental platform will non-invasively impose local micron-scale flows by manipulating optically and magnetically trapped particles, generating local flow fields in the nucleating or assembling suspension. The project brings together Strathclyde expertise in microfluidics, optical and magnetic manipulation and quantitative dynamic microscopy, and focusses on applications in the key Strathclyde research strength of advanced nanomaterial engineering and science for innovative industrial applications. It will provide a unique experimental platform to highlight Strathclyde’s developing central role in this area.
- 01-Jan-2013 - 02-Jan-2013
- Oral Biopharmaceutics "Orbito"
- Khadra, Ibrahim (Principal Investigator) Wilson, Clive (Principal Investigator) Halbert, Gavin (Principal Investigator)
- Through partnership, collaboration and data sharing, we will develop our fundamental knowledge of the gastrointestinal environment to deliver innovative biopharmaceutics tools which will accurately predict product performance over a range of clinically relevant conditions. The integration of in vitro and in silico approaches will provide a biopharmaceutics toolkit, validated using clinical data, to accelerate drug development
- 01-Jan-2012 - 01-Jan-2019
Strathclyde Institute of Pharmacy and Biomedical Sciences
View University of Strathclyde in a larger map